Oxford Cannabinoid Tech.Holdings Patent Applications (1655Z)
2024年1月10日 - 4:00PM
RNSを含む英国規制内ニュース (英語)
TIDMOCTP
RNS Number : 1655Z
Oxford Cannabinoid Tech.Holdings
10 January 2024
.
Oxford Cannabinoid Technologies Holdings plc
("OCTP" or the "Company")
Patent Applications
Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP), the
biotech company developing prescription cannabinoid medicines, is
pleased to announce that it has filed a European application in its
own name, directed to Programme 2. This programme initially targets
Trigeminal Neuralgia ("TN"), and the patent application filed by
the Company is directed to a composition containing
Delta-9-tetrahydrocannabinol ("THC") and Cannabidiol ("CBD"). The
Company intends to file an international ("PCT") patent application
based on this European application within the next year.
Once the patent is granted, OCTP will benefit from exclusive
rights to the use, production, and sale of the composition claimed
in the patent, typically for a period of up to 20 years from the
filing date. This protection potentially allows OCTP to recoup its
investment in R&D and secure a competitive market advantage.
Patent application examination times can vary, but grant of the
patent can typically be expected in 2 to 5 years from the filing
date of the patent application. The precise timing will depend on
the examination process at the patent office and any objections or
oppositions that may arise. The Company expects to file several
other patent applications directed to other aspects of Programme 2
during 2024.
Rob Bennett, General Counsel and Company Secretary of OCTP,
said:
"At OCTP, we are sharply focused on the importance of
intellectual property and patents in safeguarding our research and
development and protecting the interests of our shareholders.
Today's announcement is testimony to our ongoing research and
development strategy and our commitment to generating new
intellectual property as a pathway to commercialisation. This
European patent application further embeds our progress in relation
to Programme 2's potential, which initially targets Trigeminal
Neuralgia."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014 (which forms part of
domestic UK law pursuant to the European Union (Withdrawal) Act
2018).
The Directors of the Company accept responsibility for the
content of this announcement.
Enquiries:
O xford Cannabinoid Technologies
Holdings plc +44 (0)20 3034 2820
Clarissa Sowemimo-Coker (CEO) clarissa@oxcantech.com
Cairn Financial Advisers LLP
Emily Staples +44 (0)20 7213 0897
Jo Turner +44 (0) 20 7213 0885
Axis Capital Markets Limited
Richard Hutchison +44 (0)20 3026 0320
Acuitas Communications 020 3745 0293 / 07799 767676
Simon Nayyar simon.nayyar@acuitascomms.com
Arthur Dingemans arthur.dingemans@acuitascomms.com
About Oxford Cannabinoid Technologies Holdings Plc:
Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the
holding company of Oxford Cannabinoid Technologies Ltd (together
the "Group"), a pharmaceutical Group developing prescription
cannabinoid medicines initially targeting the US$ multi-billion
global pain market.
OCTP currently has a portfolio of four drug development
programmes. Its lead compound, OCT461201, will initially target
neuropathic and visceral pain (including irritable bowel syndrome
("IBS") and chemotherapy induced peripheral neuropathy ("CIPN").
The global market for CIPN alone is currently forecast to reach
US$1.17bn by 2028.
OCTP's drug development pipeline comprises both natural and
synthetic compounds, and includes compounds targeting trigeminal
neuralgia, a severe type of face pain, and cannabinoid derivatives
targeting pain and potentially other therapeutic areas. Having
established an exclusive licence agreement with Canopy Growth
Corporation for their entire pharmaceutical cannabinoid derivative
library, OCTP now has a portfolio of almost five hundred
derivatives and intellectual property rights including fourteen
patent families and associated research data.
OCTP has a clearly defined path to commercialisation, revenues
and growth. The Group is developing drug candidates through
clinical trials to gain regulatory approval (FDA/MHRA/EMA) that
will enable medical professionals to prescribe them with
confidence. OCTP's portfolio aims to balance risk, value and time
to market, whilst ensuring market exclusivity around all its key
activities.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDZZGGMMLFGDZZ
(END) Dow Jones Newswires
January 10, 2024 02:00 ET (07:00 GMT)
Oxford Cannabinoid Techn... (LSE:OCTP)
過去 株価チャート
から 4 2024 まで 5 2024
Oxford Cannabinoid Techn... (LSE:OCTP)
過去 株価チャート
から 5 2023 まで 5 2024